Novo Nordisk receives European Commission approval of Wegovy®️ pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved
First GLP-1 pill approved in the European Union for the treatment of obesity and overweight Only Wegovy®️ pill demonstrates 17%* mean weight loss1 and cardiovascular benefits Wegovy®️ 7.2 mg injection in a single-dose pen, delivering 21%* weight loss, has now been approved in EU Novo Nordisk today announced that the European Commission (EC) has granted marketing authorisation for Wegovy®️ pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity. This follows the positive opinion issued by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in May 2026 The Wegovy®️ pill approval is a landmark moment in the treatment of obesity in Europe, making it the first GLP-1 receptor agon...